Additionally, to determine whether silibinin alters HDAC and DNMT activity in colon cancer progression, Kauntz et al. [206] conducted a study that revealed that silibinin does not modify the activity of HDACs, but is able to significantly inhibit DNMT activity in both SW480 and SW620 cells. Here, DNMT1 is linked to colonic neoplasm.